Tectonic Therapeutic, Inc.
NASDAQ:TECXBiotechnology
-$0.29 today
- Market cap
- $411.32M
- Beta
- 1.22
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.45
Volume 0.17M
Average 0.20M
TECX Net Income
Bottom-line profit after all expenses, interest, and taxes.
Tectonic Therapeutic, Inc.NASDAQ: TECX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$25.24M, compared with -$15.91M a year earlier. Trailing-twelve-month net income was -$83.49M.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$96.5M (-30.1%) for the fiscal year ending Dec 2026, a slowdown from the -27.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$25.24M-31.3% QoQ
- Last fiscal yearDec 2025
- -$74.15M-27.9% YoY
- LTMMar 2026
- -$83.49M-42.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -58.7% | -26.7% | +32.0 pp |
| 1 year | -27.9% | -30.1% | -2.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (74.15M) USD
- Year-over-year change
- -27.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (74.15M) | -27.9% |
| FY2024 | 2024-12-31 | (57.98M) | -35.4% |
| FY2023 | 2023-12-31 | (42.82M) | -33.1% |
| FY2022 | 2022-12-31 | (32.18M) | -260.5% |
| FY2021 | 2021-12-31 | (8.93M) | — |
Net Income vs competitors
How TECX compares with its peers on the latest reported figures
- TECX's LTM Mar 2026 net income of -$83.49M is the 2nd highest of the 4 companies compared; the peer median is -$203.15M.
- Its year-over-year change of -42.3% is the lowest of 4, against a peer median of -16.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
SEPNSepterna, Inc. | LTM Sep 2026 | -$59M | -0.3% | — | 61.3% |
TECXTectonic Therapeutic, Inc. | LTM Mar 2026 | -$83.49M | -42.3% | — | — |
GENBGenerate Biomedicines, Inc. | FY2025 | -$203.15M | -16.9% | — | 637.0% |
| LTM Jun 2026 | -$215.06M | -20.2% | — | — | |
| Peer median (excluding TECX) | -$203.15M | -16.9% | — | 349.1% | |
Competitors are the stored peer set for TECX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 10.98M | 25.65M | 36.97M | 41.36M | 63.49M |
| Selling, General & Admin | 4.63M | 7.18M | 7.68M | 16.65M | 20.55M |
| Operating Expenses | 15.61M | 32.83M | 44.65M | 58.02M | 84.04M |
| Depreciation & Amortization | 364K | 1.01M | 1.48M | 1.65M | 1.38M |
| EBITDA | (8.12M) | (31.03M) | (41.19M) | (56.23M) | (71.48M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (15.61M) | (32.83M) | (44.65M) | (58.02M) | (84.04M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 149K | 581K | 4.26M | 11.3M |
| Interest Expense | 224K | 144K | 152K | 107K | 63K |
| Other Income / Expenses | 6.68M | 650K | 1.83M | 33K | 11.12M |
| Income Before Tax | (8.93M) | (32.18M) | (42.82M) | (57.98M) | (72.92M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.23M |
| Net Income | (8.93M) | (32.18M) | (42.82M) | (57.98M) | (74.15M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (33.36) | (29.05) | (11.59) | (3.93) | (4.05) |
| EPS (Diluted) | (33.36) | (29.05) | (11.53) | (3.93) | (4.05) |
| Weighted Avg Shares | 3.57M | 3.64M | 3.69M | 14.77M | 18.32M |
| Weighted Avg Shares (Diluted) | 3.57M | 3.64M | 3.71M | 14.77M | 18.32M |
Tectonic Therapeutic, Inc.
NASDAQ:TECX
Intrinsic Alpha fair value
Locked
Current Price
$21.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.